{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:32:44Z","timestamp":1792809164718,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40265-024-02018-3","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T13:02:19Z","timestamp":1712667739000},"page":"449-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Relugolix\/Estradiol\/Norethisterone Acetate: A Review in Endometriosis-Associated Pain"],"prefix":"10.1007","volume":"84","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"2018_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070750","volume":"379","author":"AW Horne","year":"2022","unstructured":"Horne AW, Missmer SA. Pathophysiology, diagnosis, and management of endometriosis. BMJ. 2022;379: e070750.","journal-title":"BMJ"},{"issue":"5","key":"2018_CR2","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.3390\/ijms24054254","volume":"24","author":"J Lamceva","year":"2023","unstructured":"Lamceva J, Uljanovs R, Strumfa I. The main theories on the pathogenesis of endometriosis. Int J Mol Sci. 2023;24(5):4254.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2018_CR3","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.3390\/ijms21082815","volume":"21","author":"E Chantalat","year":"2020","unstructured":"Chantalat E, Valera MC, Vaysse C, et al. Estrogen receptors and endometriosis. Int J Mol Sci. 2020;21(8):2815.","journal-title":"Int J Mol Sci"},{"issue":"2S","key":"2018_CR4","first-page":"73","volume":"4","author":"JC Arjona Ferreira","year":"2023","unstructured":"Arjona Ferreira JC, Migoya E. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis. Fertil Steril Rep. 2023;4(2S):73\u201382.","journal-title":"Fertil Steril Rep."},{"key":"2018_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fgwh.2021.729601","volume":"2","author":"G Barbara","year":"2021","unstructured":"Barbara G, Buggio L, Facchin F, et al. Medical treatment for endometriosis: tolerability, quality of life and adherence. Front Glob Womens Health. 2021;2: 729601.","journal-title":"Front Glob Womens Health"},{"key":"2018_CR6","unstructured":"Myovant Sciences Inc. MYFEMBREE\u00ae (relugolix, estradiol, and norethindrone acetate) tablets, for oral use: US prescribing information. 2023. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=fc3feb73-cc84-43a8-aa32-b262460495e8. Accessed 28 Feb 2024."},{"key":"2018_CR7","unstructured":"Gedeon Richter Plc. Ryeqo (relugolix\/estradiol\/norethisterone acetate) 40 mg\/1 mg\/0.5 mg film-coated tablets: EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ryeqo-epar-product-information_en.pdf. Accessed 28 Feb 2024."},{"issue":"15","key":"2018_CR8","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s40265-022-01790-4","volume":"82","author":"YY Syed","year":"2022","unstructured":"Syed YY. Relugolix\/estradiol\/norethisterone (norethindrone) acetate: a review in symptomatic uterine fibroids. Drugs. 2022;82(15):1549\u201356.","journal-title":"Drugs"},{"issue":"10343","key":"2018_CR9","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/S0140-6736(22)00622-5","volume":"399","author":"LC Giudice","year":"2022","unstructured":"Giudice LC, As-Sanie S, Arjona Ferreira JC, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet. 2022;399(10343):2267\u201379.","journal-title":"Lancet"},{"issue":"2","key":"2018_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.fertnstert.2020.07.055","volume":"115","author":"Y Osuga","year":"2021","unstructured":"Osuga Y, Seki Y, Tanimoto M, et al. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2021;115(2):397\u2013405.","journal-title":"Fertil Steril"},{"issue":"1","key":"2018_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12905-021-01393-3","volume":"21","author":"Y Osuga","year":"2021","unstructured":"Osuga Y, Seki Y, Tanimoto M, et al. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results. BMC Womens Health. 2021;21(1):250.","journal-title":"BMC Womens Health"},{"key":"2018_CR12","first-page":"e32","volume":"270","author":"R Venturella","year":"2022","unstructured":"Venturella R, As-Sanie S, Kotarski J, et al. Effects of relugolix combination therapy on endometriosis-associated pain and analgesic use in spirit studies: overall study and European populations [abstract no. 70]. Eur J Obstet Gynecol Reprod Biol. 2022;270:e32\u20133.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"2018_CR13","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/j.fertnstert.2022.08.633","volume":"118","author":"S As-Sanie","year":"2022","unstructured":"As-Sanie S, Brown EL, Imm SJ, et al. Relugolix combination therapy in North American women with endometriosis-associated pain: SPIRIT 1 and 2 trials [abstract no. P-271]. Fertil Steril. 2022;118(4):e223.","journal-title":"Fertil Steril"},{"issue":"Suppl 1","key":"2018_CR14","first-page":"i57","volume":"36","author":"C Becker","year":"2021","unstructured":"Becker C, Kotarski J, Mehedintu C, et al. The effect of time since surgical diagnosis of endometriosis on treatment outcomes with relugolix combination therapy in women with endometriosis-associated pain: SPIRIT program [abstract no. O-131]. Hum Repod. 2021;36(Suppl 1):i57.","journal-title":"Hum Repod."},{"issue":"3 Suppl","key":"2018_CR15","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.fertnstert.2021.07.146","volume":"116","author":"S As-Sanie","year":"2021","unstructured":"As-Sanie S, Mathur V, Mehedintu C, et al. Relugolix combination therapy improves multiple dimensions of quality of life in women with endometriosis-associated pain: results from the SPIRIT program [abstract no. O-118]. Fertil Steril. 2021;116(3 Suppl):e51.","journal-title":"Fertil Steril"},{"issue":"3","key":"2018_CR16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/humrep\/dead263","volume":"39","author":"CM Becker","year":"2024","unstructured":"Becker CM, Johnson NP, As-Sanie S, et al. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study. Hum Reprod. 2024;39(3):526\u201337.","journal-title":"Hum Reprod"},{"issue":"4 Suppl","key":"2018_CR17","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.fertnstert.2022.08.035","volume":"118","author":"S As-Sanie","year":"2022","unstructured":"As-Sanie S, Johnson N, Lukes AS, et al. Time to minimal or no pelvic pain with relugolix combination therapy in women with endometriosis-associated pain: results from the SPIRIT program [abstract no. 0\u201314]. Fertil Steril. 2022;118(4 Suppl):e6-7.","journal-title":"Fertil Steril"},{"issue":"Suppl 1","key":"2018_CR18","first-page":"55A","volume":"28","author":"AS Lukes","year":"2021","unstructured":"Lukes AS, As-Sanie S, Becker CM, et al. Bleeding patterns in women with endometriosis-associated pain treated with relugolix combination therapy: SPIRIT program [abstract no. O-017]. Reprod Sci. 2021;28(Suppl 1):55A.","journal-title":"Reprod Sci"},{"issue":"5 Suppl","key":"2018_CR19","doi-asserted-by":"publisher","first-page":"12S","DOI":"10.1097\/01.AOG.0000929844.43483.20","volume":"141","author":"S As-Sanie","year":"2023","unstructured":"As-Sanie S, Giudice L, Jung S, et al. Bleeding patterns with relugolix combination therapy in women with endometriosis-associated pain [abstract no. 1345374]. Obstet Gynecol. 2023;141(5 Suppl):12S.","journal-title":"Obstet Gynecol"},{"issue":"4 Suppl","key":"2018_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.fertnstert.2022.08.020","volume":"118","author":"S As-Sanie","year":"2022","unstructured":"As-Sanie S, Mehedintu C, Mathur V, et al. Sustained improvement in physical function and quality of life in women with endometriosis-associated pain treated with relugolix combination therapy over 104 weeks: SPIRIT long-term extension study [abstract no. O-1]. Fertil Steril. 2022;118(4 Suppl):e1.","journal-title":"Fertil Steril"},{"issue":"Suppl 1","key":"2018_CR21","first-page":"109","volume":"37","author":"MR McClung","year":"2022","unstructured":"McClung MR, Santora A, Johnson N, et al. Relugolix combination therapy minimizes bone loss in patients with endometriosis-associated pain: results from the phase 3 SPIRIT program [abstract no. VPP-520]. J Bone Miner Res. 2022;37(Suppl 1):109.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2018_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hropen\/hoac009","volume":"2022","author":"CM Becker","year":"2022","unstructured":"Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):1\u201326.","journal-title":"Hum Reprod Open."},{"key":"2018_CR23","unstructured":"AbbVie Inc. ORILISSA\u00ae (elagolix) tablets, for oral use: US prescribing information. 2018. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a86757b3-09c5-fd3b-1223-244e94f50a66. Accessed 28 Feb 2024."},{"issue":"11","key":"2018_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41574-019-0245-z","volume":"15","author":"C Chapron","year":"2019","unstructured":"Chapron C, Marcellin L, Borghese B, et al. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019;15(11):666\u201382.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"2018_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100748","volume":"3","author":"LHR Whitaker","year":"2022","unstructured":"Whitaker LHR, Saraswat L, Horne AW. Combination GnRH antagonists for endometriosis: balancing efficacy with side effects. Cell Rep Med. 2022;3(9): 100748.","journal-title":"Cell Rep Med."},{"key":"2018_CR26","unstructured":"US National Institutes of Health. ClinicalTrials identifier NCT05862272. 2023. https:\/\/clinicaltrials.gov. Accessed 28 Feb 2024."},{"issue":"14","key":"2018_CR27","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1021\/jm200216q","volume":"54","author":"K Miwa","year":"2011","unstructured":"Miwa K, Hitaka T, Imada T, et al. Discovery of 1-4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2011;54(14):4998\u20135012.","journal-title":"J Med Chem"},{"key":"2018_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejphar.2013.12.001","volume":"723","author":"D Nakata","year":"2014","unstructured":"Nakata D, Masaki T, Tanaka A, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014;723:167\u201374.","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 1","key":"2018_CR29","first-page":"i267","volume":"32","author":"A Lukes","year":"2017","unstructured":"Lukes A, Johnson B, Jones L, et al. Pharmacokinetics, pharmacodynamics, and safety of relugolix, a potent oral once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist, as monotherapy and in combination with estradiol\/norethindrone acetate add-back therapy [abstract no. P-287]. Hum Reprod. 2017;32(Suppl 1):i267\u20138.","journal-title":"Hum Reprod"}],"updated-by":[{"DOI":"10.1007\/s40265-024-02050-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02018-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02018-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02018-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T02:11:40Z","timestamp":1717035100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02018-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2018"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02018-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-024-02050-3","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"27 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-024-02050-3","URL":"https:\/\/doi.org\/10.1007\/s40265-024-02050-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hannah A. Blair is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}